NYSE:COV (COV) (COV) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free COV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume3.88 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (COV) alerts: Email Address Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details About (COV) Stock (NYSE:COV)Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company’s segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company’s products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.Read More Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details COV Stock News HeadlinesMay 3, 2024 | msn.comPhysicist Studying COVID-19 Believes He's Discovered Hints We're Living in a SimulationMay 1, 2024 | msn.comPeter Daszak testifying: The man behind EcoHealth Alliance and the COVID-19 origins controversyMay 4, 2024 | Behind the Markets (Ad)Investors Alert: The Next Big Thing in Weight LossUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.April 30, 2024 | msn.comScientist who gave world the Covid sequence is locked out of his lab by ChineseApril 30, 2024 | msn.comA better COVID treatment for the immunocompromised? Researchers create a non-toxic potential alternative to PaxlovidApril 30, 2024 | msn.comStudy identifies immunity threshold for protection against COVID-19 in childrenApril 30, 2024 | msn.comNew SARS-CoV-2 KP.2 variant defies vaccines with higher spread, study warnsApril 30, 2024 | finanznachrichten.deNanoViricides, Inc.: NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected SoonMay 4, 2024 | Behind the Markets (Ad)Investors Alert: The Next Big Thing in Weight LossUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.April 29, 2024 | msn.comWhat to Know About the ‘FLiRT’ Variants of COVID-19April 29, 2024 | msn.comDo SARS-CoV-2 infections cause long-term loss of smell and taste?April 29, 2024 | npr.orgQuiz: Are you smarter than an expert on how SARS-CoV-2 spreads?April 27, 2024 | bbc.comEnglish Football League - Championship Blackburn Rovers 0 Coventry City 0 Full timeApril 27, 2024 | msn.comWHO picks JN.1 variant for next set of COVID vaccinesApril 27, 2024 | msn.comCan nasal Neosporin fight COVID? Surprising new research suggests it worksApril 27, 2024 | msn.comA Man Had Covid For 613 Straight Days—and Created a Whole New MutationApril 26, 2024 | msn.comScientists discover higher levels of CO₂ increase survival of viruses in the air and transmission riskApril 26, 2024 | msn.comDid California's pediatric COVID-19 vaccination program reduce reported cases and hospitalizations?April 26, 2024 | msn.comStudy reports new compound that halts replication of COVID by targeting 'Mac-1' protein in cell modelsApril 26, 2024 | msn.comStudy suggests lingering coronavirus in tissues may contribute to long COVID symptomsApril 24, 2024 | yahoo.comScientists report longest known ‘extreme’ Covid infection in 72-year-old manApril 24, 2024 | msn.comEngineers muffle invading pathogens with a 'molecular mask'April 24, 2024 | msn.comCOVID-19 virus disrupts protein production: Researcher discusses her recent findingsApril 24, 2024 | msn.comNew tARC-seq method enhances precision in tracking SARS-CoV-2 mutationsApril 24, 2024 | msn.comRepurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infectionsApril 24, 2024 | msn.comInfluenza is considered the biggest pandemic threatApril 24, 2024 | msn.comGlobal study reveals mismatch in COVID-19 treatment guidelines with WHO standardsSee More Headlines Receive COV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (COV) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2014Today5/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryHealth Care Equipment Current SymbolNYSE:COV CUSIPG2554F11 CIK1385187 WebN/A Phone+353-1-4381700FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesGary L. Ellis (Age 61)President, Chief Executive Officer Charles J. Dockendorff (Age 63)Chief Financial Officer, Executive Vice President Bryan C. Hanson (Age 50)Group President, Covidien John H. Masterson (Age 54)Senior Vice President, General Counsel Michael P. Dunford (Age 54)Senior Vice President - Human Resources James C. Clemmer (Age 53)Senior Vice President and President - Medical Supplies Business Amy A. McBride-Wendell (Age 53)Senior Vice President - Strategy and Business Development Jacqueline F. Strayer (Age 58)Senior Vice President-Corporate Communications Michael E. Tarnoff (Age 46)Senior Vice President,Chief Medical Officer Peter L. Wehrly (Age 57)Senior Vice President, Group President - Developed Markets More Executives COV Stock Analysis - Frequently Asked Questions How were (COV)'s earnings last quarter? (COV) (NYSE:COV) posted its quarterly earnings data on Wednesday, November, 5th. The healthcare company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.13. The healthcare company earned $2.73 billion during the quarter, compared to the consensus estimate of $2.69 billion. The firm's quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.91 EPS. What other stocks do shareholders of (COV) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (COV) investors own include Pfizer (PFE), Chevron (CVX), Intel (INTC), Johnson & Johnson (JNJ), Boeing (BA), CVS Health (CVS), EMC (EMC), Gilead Sciences (GILD) and JPMorgan Chase & Co. (JPM). This page (NYSE:COV) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (COV) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.